DEC 23, 2019 8:08 AM PST

FDA Approves New Schizophrenic Drug

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) has approved an atypical antipsychotic Caplyta (lumateperone; Intra-Cellular Therapies) for the treating schizophrenia in adult patients.

Confirmation to market the drug comes from two double-blinded studies that evaluated Caplyta in schizophrenic patients for 28 days. Results were affirming and showed the taking 42mg of Caplyta daily was enough to reduce schizophrenic symptoms from baseline to Day 28.

Learn more about schizophrenia:

Like every other drug, safety is a priority Caplyta is no exception. The drug comes with a boxed warning for increased mortality rates among elderly patients receiving the medication for dementia-related psychosis. The most persist side-effects was sedation and dry mouth.

“Schizophrenia is a complex disease that severely impacts patients and their families,” said Jeffrey A. Lieberman, MD, Lawrence C. Kolb Professor and Chairman of Psychiatry, Columbia University, College of Physicians and Surgeons and Director, New York State Psychiatric Institute. “Effective treatment provided in a timely fashion can be game-changing for people living with schizophrenia. The efficacy and safety profile of Caplyta approved by the FDA, offers healthcare providers an important new option for treating people living with schizophrenia.”

How does Caplyta work? The exact mechanism remains a mystery but it is generally believed to work its magic by antagonizing the activity of particular serotonin receptors known the 5-HT2A and the postsynaptic activity of the central dopamine D2 receptors.

Caplyat will be marketed in 42mg capsules provided in 30-count boxes.

Source: IntraCellularTherapies

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 01, 2020
Drug Discovery & Development
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
OCT 01, 2020
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
It has been known for some time that the HPV vaccine protects against human papillomavirus infection, genital warts, and ...
OCT 15, 2020
Neuroscience
Neurometabolism: A bold, new frontier
OCT 15, 2020
Neurometabolism: A bold, new frontier
Billions of neurons communicate with each other through trillions of synapses to create a functioning, unique system we ...
OCT 13, 2020
Drug Discovery & Development
Uses of Tandem Mass Spectrometry (TMS)
OCT 13, 2020
Uses of Tandem Mass Spectrometry (TMS)
What is tandem mass spectrometry? A powerful analytical tool that is capable of characterizing complex mixtures in drug ...
NOV 08, 2020
Neuroscience
Psychedelic DMT Improves Memory by Neurogenesis
NOV 08, 2020
Psychedelic DMT Improves Memory by Neurogenesis
Researchers from the Complutense University of Madrid in Spain have found that dimethyltryptamine (DMT), the psychoactiv ...
NOV 12, 2020
Immunology
The Enzyme That Keeps Viruses In Stealth Mode
NOV 12, 2020
The Enzyme That Keeps Viruses In Stealth Mode
Some viral infections just don’t go away. The hepatitis C virus, for instance, can result in life-long chronic inf ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
Loading Comments...